{"title":"小剂量伊曲康唑治疗慢性特发性咳嗽的临床经验。","authors":"Haruhiko Ogawa, Masaki Fujimura, Yasuo Takeuchi, Koichi Makimura","doi":"10.1186/1745-9974-9-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong></p><p><strong>Background: </strong>The presence of basidiomycetous (BM) fungi in induced sputum is an important clinical finding in chronic idiopathic cough (CIC). However, the efficacy of anti-fungal therapy for CIC has not been evaluated.</p><p><strong>Methods: </strong>We selected 10 patients with CIC and carried out allergological examinations for Bjerkandera adusta, a BM fungus that has been shown to enhance cough severity. The efficacy of low-dose itraconazole (ITCZ) therapy (50 mg/day) for 14 days as an adjunctive therapy was estimated with use of Cough Visual Analog Scale (Cough VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ). We evaluated whether there was a recognizable clinical or allergological pattern that could predict the efficacy of ITCZ therapy in CIC patients.</p><p><strong>Results: </strong>Significant changes in Cough VAS and minimal important difference in domains of the J-LCQ were observed in 3 and 5 CIC patients, respectively. The Δ cough scale was correlated with changes in domains of the J-LCQ (total (r = -0.73, P < 0.05), psychological (r = -0.73, P < 0.05), and social (r = -0.71, P < 0.05), respectively. There were significant differences in the change in total score (P < 0.05) and in the domain of social (P < 0.05) and Δ cough scale (P < 0.05) between positive and negative results of immediate skin test for B. adusta. Positive results for improvement of cough-related laryngeal sensation which was represented as a sensation of mucus in the throat (SMIT) were observed in 6 patients in the BM colonization-positive group (85.7%) and none in the BM colonization-negative group (0%). There was a significant difference in the positive ratio for improvement of SMIT between the two groups.</p><p><strong>Conclusions: </strong>At present, it is not possible to conclude whether ITCZ therapy provides sufficient relief in CIC patients. However, this study suggested both the possible applicability of low-dose ITCZ therapy for treatment of CIC patients with regard to BM allergy and the necessity of development of a new assessment questionnaire for cough-related laryngeal sensations.</p><p><strong>Trial registration: </strong>UMIN-CTR (reference number R000005872; UMIN000004933).</p>","PeriodicalId":10747,"journal":{"name":"Cough (London, England)","volume":"9 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562166/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical experience with low-dose itraconazole in chronic idiopathic cough.\",\"authors\":\"Haruhiko Ogawa, Masaki Fujimura, Yasuo Takeuchi, Koichi Makimura\",\"doi\":\"10.1186/1745-9974-9-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Unlabelled: </strong></p><p><strong>Background: </strong>The presence of basidiomycetous (BM) fungi in induced sputum is an important clinical finding in chronic idiopathic cough (CIC). However, the efficacy of anti-fungal therapy for CIC has not been evaluated.</p><p><strong>Methods: </strong>We selected 10 patients with CIC and carried out allergological examinations for Bjerkandera adusta, a BM fungus that has been shown to enhance cough severity. The efficacy of low-dose itraconazole (ITCZ) therapy (50 mg/day) for 14 days as an adjunctive therapy was estimated with use of Cough Visual Analog Scale (Cough VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ). We evaluated whether there was a recognizable clinical or allergological pattern that could predict the efficacy of ITCZ therapy in CIC patients.</p><p><strong>Results: </strong>Significant changes in Cough VAS and minimal important difference in domains of the J-LCQ were observed in 3 and 5 CIC patients, respectively. The Δ cough scale was correlated with changes in domains of the J-LCQ (total (r = -0.73, P < 0.05), psychological (r = -0.73, P < 0.05), and social (r = -0.71, P < 0.05), respectively. There were significant differences in the change in total score (P < 0.05) and in the domain of social (P < 0.05) and Δ cough scale (P < 0.05) between positive and negative results of immediate skin test for B. adusta. Positive results for improvement of cough-related laryngeal sensation which was represented as a sensation of mucus in the throat (SMIT) were observed in 6 patients in the BM colonization-positive group (85.7%) and none in the BM colonization-negative group (0%). There was a significant difference in the positive ratio for improvement of SMIT between the two groups.</p><p><strong>Conclusions: </strong>At present, it is not possible to conclude whether ITCZ therapy provides sufficient relief in CIC patients. However, this study suggested both the possible applicability of low-dose ITCZ therapy for treatment of CIC patients with regard to BM allergy and the necessity of development of a new assessment questionnaire for cough-related laryngeal sensations.</p><p><strong>Trial registration: </strong>UMIN-CTR (reference number R000005872; UMIN000004933).</p>\",\"PeriodicalId\":10747,\"journal\":{\"name\":\"Cough (London, England)\",\"volume\":\"9 1\",\"pages\":\"1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562166/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cough (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1745-9974-9-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cough (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1745-9974-9-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical experience with low-dose itraconazole in chronic idiopathic cough.
Unlabelled:
Background: The presence of basidiomycetous (BM) fungi in induced sputum is an important clinical finding in chronic idiopathic cough (CIC). However, the efficacy of anti-fungal therapy for CIC has not been evaluated.
Methods: We selected 10 patients with CIC and carried out allergological examinations for Bjerkandera adusta, a BM fungus that has been shown to enhance cough severity. The efficacy of low-dose itraconazole (ITCZ) therapy (50 mg/day) for 14 days as an adjunctive therapy was estimated with use of Cough Visual Analog Scale (Cough VAS) and the Japanese version of the Leicester Cough Questionnaire (J-LCQ). We evaluated whether there was a recognizable clinical or allergological pattern that could predict the efficacy of ITCZ therapy in CIC patients.
Results: Significant changes in Cough VAS and minimal important difference in domains of the J-LCQ were observed in 3 and 5 CIC patients, respectively. The Δ cough scale was correlated with changes in domains of the J-LCQ (total (r = -0.73, P < 0.05), psychological (r = -0.73, P < 0.05), and social (r = -0.71, P < 0.05), respectively. There were significant differences in the change in total score (P < 0.05) and in the domain of social (P < 0.05) and Δ cough scale (P < 0.05) between positive and negative results of immediate skin test for B. adusta. Positive results for improvement of cough-related laryngeal sensation which was represented as a sensation of mucus in the throat (SMIT) were observed in 6 patients in the BM colonization-positive group (85.7%) and none in the BM colonization-negative group (0%). There was a significant difference in the positive ratio for improvement of SMIT between the two groups.
Conclusions: At present, it is not possible to conclude whether ITCZ therapy provides sufficient relief in CIC patients. However, this study suggested both the possible applicability of low-dose ITCZ therapy for treatment of CIC patients with regard to BM allergy and the necessity of development of a new assessment questionnaire for cough-related laryngeal sensations.
Trial registration: UMIN-CTR (reference number R000005872; UMIN000004933).